<div><div></div><div>On December 10, 2025, Tharimmune, Inc. announced the appointment of Jacob Asbury as Chief Financial Officer, effective immediately. He succeeds Sireesh Appajosyula, who will continue as CEO of Gravitas Life Sciences, Inc., a subsidiary of Tharimmune.<div><table><tbody><tr><td>Individual</td><td>Jacob Asbury</td><td>Sireesh Appajosyula</td></tr><tr><td>Role</td><td>Chief Financial Officer</td><td>Interim Chief Financial Officer</td></tr><tr><td>Type of Change</td><td>Appointed</td><td>Stepped down</td></tr><tr><td>Effective Date</td><td>Dec 10, 2025</td><td>Dec 10, 2025</td></tr><tr><td>Reason</td><td>N/A</td><td>Continues as CEO of subsidiary</td></tr><tr><td>Replacement Info</td><td>N/A</td><td>Jacob Asbury</td></tr><tr><td>Background Details</td><td>Former CFO of Clear Street Group, Inc.</td><td>N/A</td></tr><tr><td>Board/Committee Role Changes</td><td>Not disclosed</td><td>Not disclosed</td></tr></tbody></table></div>Original SEC Filing: Tharimmune, Inc. [ THAR ] - 8-K - Dec. 12, 2025<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

THAR

Tharimmune, Inc. has appointed Jacob Asbury as the new Chief Financial Officer, effective December 10, 2025. He replaces Sireesh Appajosyula, who will continue as CEO of Gravitas Life Sciences, a subsidiary of Tharimmune. Jacob Asbury was previously the CFO of Clear Street Group, Inc. This change was announced in an 8-K filing with the SEC on December 12, 2025.

Tharimmune, Inc. Appoints New Chief Financial Officer